{"DataElement":{"publicId":"6763382","version":"1","preferredName":"Immunotherapy Agent Administered Type","preferredDefinition":"The response to a question asking about the type of immunotherapy agents administered to a patient during anti-cancer therapy.","longName":"IMM_AG_ADMIN_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6763377","version":"1","preferredName":"Immunotherapy Agent Administered","preferredDefinition":"Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments. Agents used in immunotherapy include monoclonal antibodies, growth factors, and vaccines. These agents may also have a direct antitumor effect._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The act of having given something (e.g., a medication or test).","longName":"6763375v1.0:2233610v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6763375","version":"1","preferredName":"Immunotherapy Agent","preferredDefinition":"Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments. Agents used in immunotherapy include monoclonal antibodies, growth factors, and vaccines. These agents may also have a direct antitumor effect.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C15262:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"895A8F2F-991D-5DA3-E053-F662850ABC81","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"895A8F2F-992B-5DA3-E053-F662850ABC81","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-20","modifiedBy":"SETRAKIN","dateModified":"2019-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6763378","version":"1","preferredName":"Immunotherapy Agent Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6763378v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Inotuzumab","valueDescription":"Inotuzumab Ozogamicin","ValueMeaning":{"publicId":"5577157","version":"1","preferredName":"Inotuzumab Ozogamicin","longName":"5577157","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-09D6-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89958C51-8B9B-7976-E053-F662850A0954","beginDate":"2019-05-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-23","modifiedBy":"ONEDATA","dateModified":"2019-05-23","deletedIndicator":"No"},{"value":"CD22 CART cell therapy","valueDescription":"CD22 CART cell therapy","ValueMeaning":{"publicId":"6763379","version":"1","preferredName":"CD22 CART cell therapy","longName":"6763379","preferredDefinition":"CD22 CART cell therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"895AA03B-85B3-74C3-E053-F662850AA2BD","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E999F14-655A-4328-E053-F662850AA797","beginDate":"2019-07-26","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","deletedIndicator":"No"},{"value":"CD19 CART cell therapy","valueDescription":"CD19 Gene Chimeric Antigen Receptor T-cell Therapy","ValueMeaning":{"publicId":"6767195","version":"1","preferredName":"CD19 Gene Chimeric Antigen Receptor T-cell Therapy","longName":"6767195","preferredDefinition":"This gene plays a role in signal transduction and regulates the response of B cells to antigens.: Treatment that uses T-cells that have been engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CD19 Gene","conceptCode":"C38886","definition":"This gene plays a role in signal transduction and regulates the response of B cells to antigens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chimeric Antigen Receptor T-cell Therapy","conceptCode":"C155798","definition":"Treatment that uses T-cells that have been engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89958C51-8B72-7976-E053-F662850A0954","latestVersionIndicator":"Yes","beginDate":"2019-05-23","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-23","modifiedBy":"ONEDATA","dateModified":"2019-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89958C51-8B8D-7976-E053-F662850A0954","beginDate":"2019-05-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-23","modifiedBy":"ONEDATA","dateModified":"2019-05-23","deletedIndicator":"No"},{"value":"Blinatumomab","valueDescription":"Blinatumomab","ValueMeaning":{"publicId":"3690103","version":"1","preferredName":"Blinatumomab","longName":"3690103","preferredDefinition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E36-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"895AA03B-85F9-74C3-E053-F662850AA2BD","beginDate":"2019-05-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2757951","version":"1","preferredName":"Other","longName":"2757951","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F52A8FB-E278-3426-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concept to value meaning. mc 3/20/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89949210-F209-2DD9-E053-F662850AE0C2","beginDate":"2019-05-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-23","modifiedBy":"ONEDATA","dateModified":"2019-05-23","deletedIndicator":"No"},{"value":"NK Cell","valueDescription":"NK Cell","ValueMeaning":{"publicId":"8062270","version":"1","preferredName":"NK Cell","longName":"8062270","preferredDefinition":"NK Cell","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D91A5866-21C5-61FB-E053-4EBD850A0AF5","latestVersionIndicator":"Yes","beginDate":"2022-02-28","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D91A5866-21DE-61FB-E053-4EBD850A0AF5","beginDate":"2022-02-28","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-02-28","modifiedBy":"ONEDATA","dateModified":"2022-02-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"895AA03B-8592-74C3-E053-F662850AA2BD","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-20","modifiedBy":"COOPERJ","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Immunotherapy agents administ","type":"Preferred Question Text","description":"Immunotherapy agents administered:","url":null,"context":"COG"},{"name":"COG CRF text 1","type":"Alternate Question Text","description":"Specify type of cellular therapy administered:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"895AA03B-8626-74C3-E053-F662850AA2BD","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-05-20","modifiedBy":"COOPERJ","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}